Operator

Good afternoon, and welcome to Verastem Oncology's First Quarter 2026 Earnings Conference Call. My name is Daniel, and I will be your call operator today. Please note, this event is being recorded. [Operator Instructions].

I will now turn the call over to Julissa Viana, Vice President of Corporate Communications, Investor Relations and Patient Advocacy for Verastem Oncology. Please go ahead.

Julissa Viana
Vice President of Corporate Communications & Investor Relations

Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verastem's first quarter 2026 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with a slide presentation that will be referenced during our call today. Both are available on the Investor Relations section of our website.

Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we will be discussing certain non-GAAP financial measures. Reconciliations to the